作者
Giacomo Lanzoni, Elina Linetsky, Diego Correa, Shari Messinger Cayetano, Roger A Alvarez, Dimitrios Kouroupis, Ana Alvarez Gil, Raffaella Poggioli, Phillip Ruiz, Antonio C Marttos, Khemraj Hirani, Crystal A Bell, Halina Kusack, Lisa Rafkin, David Baidal, Andrew Pastewski, Kunal Gawri, Clarissa Leñero, Alejandro MA Mantero, Sarah W Metalonis, Xiaojing Wang, Luis Roque, Burlett Masters, Norma S Kenyon, Enrique Ginzburg, Xiumin Xu, Jianming Tan, Arnold I Caplan, Marilyn K Glassberg, Rodolfo Alejandro, Camillo Ricordi
发表日期
2021/5/1
期刊
Stem cells translational medicine
卷号
10
期号
5
页码范围
660-673
出版商
Oxford University Press
简介
Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects and could yield beneficial effects in COVID-19 ARDS. The objective of this study was to determine safety and explore efficacy of umbilical cord mesenchymal stem cell (UC-MSC) infusions in subjects with COVID-19 ARDS. A double-blind, phase 1/2a, randomized, controlled trial was performed. Randomization and stratification by ARDS severity was used to foster balance among groups. All subjects were analyzed under intention to treat design. Twenty-four subjects were randomized 1:1 to either UC-MSC treatment (n = 12) or the control group (n = 12). Subjects in the UC-MSC treatment group received two intravenous infusions (at day 0 and 3) of 100 ± 20 × 106 UC-MSCs; controls received two infusions of vehicle solution …
学术搜索中的文章
G Lanzoni, E Linetsky, D Correa… - Stem cells translational medicine, 2021